Immuneering Corporation (IMRX) Reports In-Line Q2 EPS

Immuneering Corporation (NASDAQ: IMRX) reported Q2 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Immuneering Corporation (IMRX) click here.

You May Also Be Interested In

• Iran's foreign ministry spokesperson: geographic characteristics of the route in Strait of Hormuz agreed by Iran and Oman
• Avnet (AVT) Tops Q4 EPS by 61c; offers guidance
• Brink's (BCO) Tops Q2 EPS by 8c ; Offers Guidance